Selecta Biosciences Inc. (NASDAQ:SELB) has a beta value of 0.95 and has seen 2,654,860 shares traded in the last trading session. The company, currently valued at $337.12 Million, closed the last trade at $3 per share which meant it lost -$0.15 on the day or -4.76% during that session. The SELB stock price is -90% off its 52-week high price of $5.7 and 51% above the 52-week low of $1.47. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.07 Million shares traded. The 3-month trading volume is 1.91 Million shares.
The consensus among analysts is that Selecta Biosciences Inc. (SELB) is a Buy stock at the moment, with a recommendation rating of 1.9. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 7 have rated it as a Hold, with 6 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.12.
Selecta Biosciences Inc. (NASDAQ:SELB) trade information
Despite being -4.76% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Apr 27 when the SELB stock price touched $4.04-2 or saw a rise of 25.74%. Year-to-date, Selecta Biosciences Inc. shares have moved -0.99%, while the 5-day performance has seen it change -21.87%. Over the past 30 days, the shares of Selecta Biosciences Inc. (NASDAQ:SELB) have changed -25.19%. Short interest in the company has seen 6.81 Million shares shorted with days to cover at 3.57.
Wall Street analysts have a consensus price target for the stock at $7.67, which means that the shares’ value could jump 155.67% from current levels. The projected low price target is $3 while the price target rests at a high of $13. In that case, then, we find that the current price level is +333.33% off the targeted high while a plunge would see the stock lose 0% from current levels.
Selecta Biosciences Inc. (SELB) estimates and forecasts
Figures show that Selecta Biosciences Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -10.71% over the past 6 months, with this year growth rate of 57.35%, compared to 8.1% for the industry. Other than that, the company has, however Increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 42.9% and 60% for the next quarter. Revenue growth from the last financial year stood is estimated to be +129%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +29.4% over the past 5 years. Earnings growth for 2021 is a modest +44%.
Selecta Biosciences Inc. (NASDAQ:SELB)’s Major holders
Insiders own 24.93% of the company shares, while shares held by institutions stand at 52.97% with a share float percentage of 70.57%. Investors are also buoyed by the number of investors in a company, with Selecta Biosciences Inc. having a total of 137 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 5.47 Million shares worth more than $16.59 Million. As of December 30, 2020, Blackrock Inc. held 4.87% of shares outstanding.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The other major institutional holder is Vanguard Group Inc. (The), with the holding of over 5Million shares as of December 30, 2020. The firm’s total holdings are worth over $15.15 Million and represent 4.45% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of December 30, 2020, the former fund manager holds about 2.21% shares in the company for having 2486936 shares of worth $7.54 Million while later fund manager owns 1.68 Million shares of worth $7.59 Million as of March 30, 2021, which makes it owner of about 1.49% of company’s outstanding stock.